TY - JOUR
T1 - The Frequency of Urination Dysfunction in Patients Operated on for Rectal Cancer
T2 - A Systematic Review with Meta-Analyses
AU - Ágústsdóttir, Dagný Halla
AU - Öberg, Stina
AU - Christophersen, Camilla
AU - Oggesen, Birthe Thing
AU - Rosenberg, Jacob
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024
Y1 - 2024
N2 - The frequency of long-term urination dysfunction after surgery for rectal cancer remains unclear, yet it is essential to establish this to improve treatment strategies. Randomized controlled trials (RCTs), non-RCTs, and cohort studies were included with patients having undergone sphincter-preserving total (TME) or partial mesorectal excision (PME) for the treatment of primary rectal cancer in this review. The outcome was urination dysfunction reported at least three months postoperatively, both overall urination dysfunction and subdivided into specific symptoms. The online databases PubMed, Embase, and Cochrane CENTRAL were searched, bias was assessed using the Newcastle–Ottawa scale, and results were synthesized using one-group frequency meta-analyses. A total of 55 studies with 15,072 adults were included. The median follow-up was 29 months (range 3–180). The pooled overall urination dysfunction was 21% (95% confidence interval (CI) 12%–30%) 3–11 months postoperatively and 25% (95% CI 19%–32%) ≥12 months postoperatively. Retention and incontinence were common 3–11 months postoperatively, with pooled frequencies of 11% and 14%, respectively. Increased urinary frequency, retention, and incontinence seemed even more common ≥12 months postoperatively, with pooled frequencies of 37%, 20%, and 23%, respectively. In conclusion, one in five patients experienced urination dysfunction more than a year following an operation for rectal cancer.
AB - The frequency of long-term urination dysfunction after surgery for rectal cancer remains unclear, yet it is essential to establish this to improve treatment strategies. Randomized controlled trials (RCTs), non-RCTs, and cohort studies were included with patients having undergone sphincter-preserving total (TME) or partial mesorectal excision (PME) for the treatment of primary rectal cancer in this review. The outcome was urination dysfunction reported at least three months postoperatively, both overall urination dysfunction and subdivided into specific symptoms. The online databases PubMed, Embase, and Cochrane CENTRAL were searched, bias was assessed using the Newcastle–Ottawa scale, and results were synthesized using one-group frequency meta-analyses. A total of 55 studies with 15,072 adults were included. The median follow-up was 29 months (range 3–180). The pooled overall urination dysfunction was 21% (95% confidence interval (CI) 12%–30%) 3–11 months postoperatively and 25% (95% CI 19%–32%) ≥12 months postoperatively. Retention and incontinence were common 3–11 months postoperatively, with pooled frequencies of 11% and 14%, respectively. Increased urinary frequency, retention, and incontinence seemed even more common ≥12 months postoperatively, with pooled frequencies of 37%, 20%, and 23%, respectively. In conclusion, one in five patients experienced urination dysfunction more than a year following an operation for rectal cancer.
KW - late complications
KW - rectal cancer
KW - total mesorectal excision
KW - urinary incontinence
KW - urinary retention
KW - urination disorders
U2 - 10.3390/curroncol31100442
DO - 10.3390/curroncol31100442
M3 - Review
C2 - 39451746
AN - SCOPUS:85207368070
VL - 31
SP - 5929
EP - 5942
JO - Current Oncology
JF - Current Oncology
SN - 1198-0052
IS - 10
ER -